Phase 2 N=30 Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
Alopecia Areata
Primary: Percent Change From Baseline in SALT Score at Week 24 — -12.6 percent change in score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=88 Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Opioid Use Disorder
Primary: Area Under the Plasma Concentration-time Curve From Study Day 1 to Day 29 (AUC0-28days) of Buprenorphine — 1640; 1720; 1570; 1870 h*ng/mL
N/A N=63 In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables
Dementia · Mild Cognitive Impairment · Alzheimer Disease
Primary: 3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D) — 18; 14.85 units on a scale
N/A N=15 In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Rural Homes
Dementia · Mild Cognitive Impairment · Alzheimer Disease
Primary: 3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D) — 17.71; 18.6 units on a scale
Phase 2 N=86 Tafenoquine in Patients With Mild to Moderate COVID-19
COVID 19 Disease
Primary: Number of Patients With Clinical Recovery of COVID-19 Symptoms on Day 14 — 8; 10; 37; 31 Participants — p=0.1879
N/A N=536 Promoting Informed Decisions About Cancer Screening in Older Adults
Colorectal Cancer Screening
Primary: Shared Decision Making Process (SDMP) Scale Score — 1.1; 1.5 Score on a scale — p=.011
Phase 3 N=267 Confirmatory Study of BK1310 in Healthy Infants
Tetanus · Diphtheria · Pertussis
Primary: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants…
Phase 3 N=771 Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
Coronavirus Disease 2019 (COVID-19)
Primary: Number of Participants With COVID-19 Progression to a More Severe Form — 59; 89 Participants — p=0.0088
N/A N=155 Philips Intracardiac Echocardiography (ICE) Clinical Registry
Atrial Fibrillation · Stroke · Valve Disease, Heart
Primary: Technical Success — 153 Participants
N/A N=4,110 A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)
Depression · Acute Pain · Chronic Pain
Primary: Number of Individuals Identified as Potential Participants Through EHR (Electronic Health Record) — 17,496 Participants
Phase 1 N=18 Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Sepsis · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants With Adverse Events — 3; 4; 5; 4 Participants
Phase 3 N=128 Ertugliflozin for Functional Mitral Regurgitation
Mitral Valve Insufficiency · Left Ventricular Systolic Dysfunction
Primary: Change of EROA — 0.03; -0.05 square cm — p=<0.001
N/A N=103 A Post-Market Clinical Evaluation of the Treatment of Tibia Fractures With the T2 Alpha Tibia Nailing System
Tibial Fractures
Primary: SF-36 PCS (36-Item Short Form Health Survey Physical Component Summary) — 49.21 score on a scale
Phase 1 N=26 Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Drug-Drug Interaction · Heathy Volunteer
Primary: Cmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug — 50482.44; 53345.17; 46510.23; 12695.07 pg/mL
Phase 1 N=42 A Study of RBT-9 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
Healthy Volunteers · Chronic Kidney Disease
Primary: Effect of RBT-9 on Plasma Ferritin Levels — -9.83; 7.66; 39.37 Percent change from baseline